Real‑world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE‑SEARCH study

• Ana María López Muñoz ^[1] ; Encarnación González Flores ^[2] ; Alberto Carral Maseda ^[3] ; Paola Pimentel Cáceres ^[4] ; Ruth Afonso Gómez ^[5] ; Carlos López López ^[6] ; Raquel Jimeno Maté ^[6] ; Juan José Reina Zoilo ^[7] ; Carmen Castañón López ^[8] ; Mercedes Salgado Fernández ^[10] ; Jorge Aparicio Urtasun ^[11] ; Elena Asensio Martínez ^[9] ; Teresa Martín Gómez ^[12]
  1. [1] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  2. [2] Hospital Universitario Virgen de las Nieves

     Hospital Universitario Virgen de las Nieves

     Granada, España

     
  3. [3] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  4. [4] Hospital General Universitario Santa Lucía

     Hospital General Universitario Santa Lucía

     Cartagena, España

     
  5. [5] Hospital Universitario Nuestra Señora de Candelaria

     Hospital Universitario Nuestra Señora de Candelaria

     Santa Cruz de Tenerife, España

     
  6. [6] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  7. [7] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  8. [8] Complejo Asistencial Universitario de León

     Complejo Asistencial Universitario de León

     León, España

     
  9. [9] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  10. [10] Medical Oncology, Complejo Hospitalario Universitario Ourense, Ourense, Spain
  11. [11] Medical Oncology, Hospital Universitario y Politécnico la Fe, Valencia, Spain
  12. [12] Medical Oncology, Hospital Universitario Salamanca, Salamanca, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 3, 2025, págs. 1176-1184
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To describe the dosing patterns of regorafenib in a real-world population of patients with metastatic colorectal cancer (mCRC) in a routine clinical practice setting in Spain, focusing on the starting dose of regorafenib.

    Methods An observational, retrospective, multicenter study that included patients≥18 years old who had histologically documented mCRC and who had initiated treatment with regorafenib since January 2017. Post hoc categorization of dosing patterns revealed the following: initial dose<160 mg and dose escalation, initial dose<160 mg and maintenance, initial dose equal to 160 mg and maintenance, and initial dose equal to 160 mg and dose reduction.

    Results Most patients (152/241, 63.8%) initiated treatment with regorafenib at doses<160 mg. There was large variation in the starting dose of regorafenib over time: in 2017, most patients (59%) initiated regorafenib at a dose of 160 mg, this proportion decreased to 6% in 2021. There were no signifcant diferences in the median progression-free survival according to the regorafenib dose patterns during the frst two cycles. The proportion of patients who reported at least one adverse event (AE), had a grade 3–4 AE or had an AE leading to dose reduction was greater in the group of patients who received an initial dose equal to 160 and reduction.

    Conclusions Our results indicate that physicians in Spain have gradually adopted a dose-escalation approach during cycle 1, which is a common practice for starting treatment with a reduced dose (<160 mg/day), a strategy that seems to improve tolerability while maintaining efcacy